Plus therapeutics to present at the 2022 q2 investor summit

Austin, texas, april 26, 2022 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that marc hedrick, m.d., president and chief executive officer, will present at the 2022 q2 investor summit on tuesday, may 3, 2022, at 12:30 p.m. et at the westin new york grand central, new york, n.y.
PSTV Ratings Summary
PSTV Quant Ranking